18.4 C
New York

Tag: Advancement

The Impact of Artificial Intelligence on The Online Casino Industry

Online casinos are a result of technological advancement. And since its emergence, there has been a lot of improvement. Today, there are a lot...

Top News

Online football betting and withdrawal

A proposition that is too difficult for you to even consider rejecting. We sympathise with inexperienced card sharks who are strapped for cash. You...

A true representative of the peak mobile gaming experience?

From the uncertain glances looming upon it by the gaming industry back a decade ago to stretching itself as an estimated $94.8 Billion Global...

The Stark Uptick in the Space & Satellite Industry

The number of satellites circling the earth has skyrocketed in recent years. In 1959 the number was only two but today there are over three thousand active satellites, and that is just the beginning. Private companies are scrambling to conquer space at a rapid pace. SpaceX’s Starlink project alone has the permission to put 12000 […]

The post The Stark Uptick in the Space & Satellite Industry appeared first on ELE Times.

What Is Next for Malta, the First EU Country To Legalize Cannabis?

Plant Medicine Week is dedicated to the recognition and advancement of the healing powers of cannabis and psychedelics—the event will take place in Valletta, Malta from April 5-8.

The post What Is Next for Malta, the First EU Country To Legalize Cannabis? appeared first on High Times.

Timelapse: Rec Room Paintball Recreated In Horizon Worlds

This minute-long timelapse video shows the ground-up creation of a Horizon World game much like Rec Room paintball.

Kindstar Globalgene Announces FY2021 Annual Results, Revenue Increases to RMB930.67 Million

Tag Template - News Hub PRO

HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").

During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.

Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas

Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.

-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively.
-- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively.
-- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively.
-- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year.
-- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively.
-- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year.
-- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.

Persistent R&D investment to develop and expand new specialty esoteric testing business lines

As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.

-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers.
-- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy.
-- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.

Entered the IVD reagents field and optimized immune repertoire deployment

Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.

As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.

Strategy and Prospects

The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.

Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."

Kindstar Globalgene 2021 Annual Results Announcement:
https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0325/2022032501238.pdf

Infographics for Kindstar Globalgene 2021 Annual Results Announcement:
https://mp.weixin.qq.com/s/h1rKtS_79dJ-Symd7Prz0w

About Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.

The Group's website: https://www.kindstar.com.cn/tc/



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
Tag Template - News Hub PRO

Forza Horizon 5 getting a trunkload of content in Series 6 update

Forza Horizon 5 Pc Series 6 Open DoorsThe Forza Horizon 5 content update, Series 6, celebrates the fast and fascinating creations of its community. Officially dubbed as the “Horizon Customs” update, this brings upgrades to both the Horizon Open and EventLab game modes, which are big parts of the Forza Horizon 5 experience. There’s also a new series of events for Horizon Story coming called Drift Club Mexico. It is spearheaded by the arrival of the new all-electric 2021 Ford Mustang Mach-E 1400, in addition to “seven of the world’s coolest drift cars.”   Open roads for all One big advancement coming to the Horizon Open game mode is Custom Racing. Players can now matchmake with others of equal preferences, allowing different options such as PI class and type of race to be tailored. For those who frequent Horizon Open in Forza Horizon 5, you’ll be happy to know that this mode will now have its own progression system. Said system applies to Open Racing, Drifting, and Playground...

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Committed to Driving Bitcoin Adoption via Lightning Network Offering; Network Tripled Capacity in 2021

The Lightning Network provides instant payment transfers/settlement times, scalability, low costs/fees, and works across blockchain with the same cryptographic hash function The Network’s capacity grew from 1,089 BTC to 3,479 BTC in 12 months LQwD’s active public nodes on the Lightning Network include France, England, Singapore, Sweden, Italy, Indonesia, Germany, Ireland, and the U.S. and … Continue reading "LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Committed to Driving Bitcoin Adoption via Lightning Network Offering; Network Tripled Capacity in 2021"

The post LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Committed to Driving Bitcoin Adoption via Lightning Network Offering; Network Tripled Capacity in 2021 appeared first on CryptoCurrencyWire.

Aurora Cannabis Acquires Thrive Cannabis and its Award-Winning Greybeard Brand

EDMONTON, Alberta – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to announce today that the Company […]

AI Advances Lead To Improvements in E-Signatures

With the advancement of digital technology, electronic signatures (e-signatures) have gained massive acceptance in the business world, where artificial intelligence (AI) further leads its improvements.  What Are E-Signatures? E-signatures, or the digitized or scanned version of handwritten signatures, improve business processes, allowing fast signing and approval of documents. They are used to verify digital documents […]

The post AI Advances Lead To Improvements in E-Signatures appeared first on SmartData Collective.

FTX Acquires Good Luck Games In Its Quest For NFT Gaming

FTX Good Luck Games

Bahamian-based FTX, one of the biggest cryptocurrency exchange platforms in the world, has announced the acquisition of Good Luck Games in a bid to attract gamers into the world of NFTs and blockchain.  According to FTX’s CEO, in its mission to study the convergence of NFTs, cryptocurrency, and gaming, the company has found the ideal partner in the team at Good Luck Games. This acquisition represents the company’s first venture into in-house game production, as well as a significant step forward in its continuing endeavor to establish blockchain-based virtual assets as a widely recognized business plan in the gaming industry. As part of FTX’s broader commitment to climate and carbon neutrality, FTX’s Gaming team will concentrate on incorporating environmentally friendly blockchain technology into its operations. Why is FTX acquiring Good Luck Games? Good Luck Games (GLG) is an independent game development studio that is responsible for the development and publication of the famous upcoming card auto battle game Storybook Brawl. It was launched in 2019 by a group of seasoned card game designers and former professional card game players who wanted to do something different. FTX is now aiming to assist the team in developing as many games as they possibly can, with the goal of integrating the games as much as possible with FTX. As part of the advancement, FTX’s booth at this week’s Game Developers Conference in San Francisco will have an art-based NFT demo of Storybook Brawl on display for attendees. Crypto firms are attempting to capitalize on the expanding gaming sector by implementing NFTs and blockchain technology into their operations. A decentralized gaming future might be realized with the introduction of blockchain technology to the gaming industry, in which assets earned or bought in one game could be transferred and utilized in another game. It is FTX’s intention to take the lead in this new initiative, and the company believes that bringing on board the Storybook Brawl and the Good Luck Games team is a significant first step toward attaining widespread adoption of NFTs and blockchain technology across the gaming industry.

The post FTX Acquires Good Luck Games In Its Quest For NFT Gaming appeared first on Cryptoknowmics-Crypto News and Media Platform.

Tesla to provide Megapacks for 300MWh project with Australia’s Edify Energy

Tesla will provide a 150MW/300MWh energy storage system with its Megapacks in Australia for three new projects from Edify Energy. Edify Energy is an Australian solar and battery storage developer and has chosen Tesla to provide the massive battery energy storage systems (BESS) for a series of projects in New South Wales. The projects, located […]

The post Tesla to provide Megapacks for 300MWh project with Australia’s Edify Energy appeared first on TESLARATI.

Tag Template - News Hub PRO

Recent articles

spot_img